These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 27465922

  • 1. Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells.
    Parmar MB, Arteaga Ballesteros BE, Fu T, K C RB, Montazeri Aliabadi H, Hugh JC, Löbenberg R, Uludağ H.
    J Biomed Mater Res A; 2016 Dec; 104(12):3031-3044. PubMed ID: 27465922
    [Abstract] [Full Text] [Related]

  • 2. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
    Parmar MB, Meenakshi Sundaram DN, K C RB, Maranchuk R, Montazeri Aliabadi H, Hugh JC, Löbenberg R, Uludağ H.
    Acta Biomater; 2018 Jan 15; 66():294-309. PubMed ID: 29183848
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
    Falamarzian A, Aliabadi HM, Molavi O, Seubert JM, Lai R, Uludağ H, Lavasanifar A.
    J Biomed Mater Res A; 2014 Sep 15; 102(9):3216-28. PubMed ID: 24167124
    [Abstract] [Full Text] [Related]

  • 6. siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers.
    Sahin B, Fife J, Parmar MB, Valencia-Serna J, Gul-Uludağ H, Jiang X, Weinfeld M, Lavasanifar A, Uludağ H.
    Biomaterials; 2014 Nov 15; 35(34):9382-94. PubMed ID: 25128374
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines.
    Parmar MB, Aliabadi HM, Mahdipoor P, Kucharski C, Maranchuk R, Hugh JC, Uludağ H.
    Front Bioeng Biotechnol; 2015 Nov 15; 3():14. PubMed ID: 25763370
    [Abstract] [Full Text] [Related]

  • 9. Small hydrophobe substitution on polyethylenimine for plasmid DNA delivery: Optimal substitution is critical for effective delivery.
    Thapa B, Plianwong S, Remant Bahadur KC, Rutherford B, Uludağ H.
    Acta Biomater; 2016 Mar 15; 33():213-24. PubMed ID: 26802444
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.
    Montazeri Aliabadi H, Landry B, Mahdipoor P, Uludağ H.
    Mol Pharm; 2011 Oct 03; 8(5):1821-30. PubMed ID: 21838308
    [Abstract] [Full Text] [Related]

  • 12. In Vivo Delivery of siRNAs Targeting EGFR and BRD4 Expression by Peptide-Modified Redox Responsive PEG-PEI Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
    Wan X, Sun R, Bao Y, Zhang C, Wu Y, Gong Y.
    Mol Pharm; 2021 Nov 01; 18(11):3990-3998. PubMed ID: 34591491
    [Abstract] [Full Text] [Related]

  • 13. A novel tyrosine-modified low molecular weight polyethylenimine (P10Y) for efficient siRNA delivery in vitro and in vivo.
    Ewe A, Przybylski S, Burkhardt J, Janke A, Appelhans D, Aigner A.
    J Control Release; 2016 May 28; 230():13-25. PubMed ID: 27061141
    [Abstract] [Full Text] [Related]

  • 14. Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.
    Aliabadi HM, Mahdipoor P, Kucharsky C, Chan N, Uludağ H.
    Pharm Res; 2015 Dec 28; 32(12):3813-26. PubMed ID: 26129766
    [Abstract] [Full Text] [Related]

  • 15. The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.
    Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludağ H.
    Biomaterials; 2010 Feb 28; 31(6):1420-8. PubMed ID: 19913908
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
    Okamoto A, Asai T, Hirai Y, Shimizu K, Koide H, Minamino T, Oku N.
    Mol Pharm; 2018 Apr 02; 15(4):1495-1504. PubMed ID: 29502423
    [Abstract] [Full Text] [Related]

  • 18. Breathing New Life into TRAIL for Breast Cancer Therapy: Co-Delivery of pTRAIL and Complementary siRNAs Using Lipopolymers.
    Thapa B, Kc R, Bahniuk M, Schmitke J, Hitt M, Lavasanifar A, Kutsch O, Seol DW, Uludag H.
    Hum Gene Ther; 2019 Dec 02; 30(12):1531-1546. PubMed ID: 31547718
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Precision combination therapy for triple negative breast cancer via biomimetic polydopamine polymer core-shell nanostructures.
    Ding Y, Su S, Zhang R, Shao L, Zhang Y, Wang B, Li Y, Chen L, Yu Q, Wu Y, Nie G.
    Biomaterials; 2017 Jan 02; 113():243-252. PubMed ID: 27829203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.